USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$29.89M
Market Cap
-
P/E Ratio
-0.21
EPS
$594.00
52 Week High
$4.44
52 Week Low
HEALTHCARE
Sector
| Field | Value (None) |
|---|---|
| Gross Profit | $5.1M |
| Total Revenue | $8M |
| Cost Of Revenue | $2.9M |
| Costof Goods And Services Sold | $2.9M |
| Operating Income | -$7.7M |
| Selling General And Administrative | $6.9M |
| Research And Development | $1.8M |
| Operating Expenses | $13M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $22K |
| Income Before Tax | -$7.1M |
| Income Tax Expense | $39K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$6.7M |
| Ebitda | -$6.6M |
| Net Income | -$7.1M |
| Field | Value (None) |
|---|---|
| Total Assets | $4.8M |
| Total Current Assets | $4.6M |
| Cash And Cash Equivalents At Carrying Value | $693K |
| Cash And Short Term Investments | $693K |
| Inventory | $2.5M |
| Current Net Receivables | $1M |
| Total Non Current Assets | $205K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $407K |
| Other Non Current Assets | - |
| Total Liabilities | $5M |
| Total Current Liabilities | $5M |
| Current Accounts Payable | $2.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $926K |
| Total Non Current Liabilities | $61K |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $967K |
| Other Current Liabilities | $1.1M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$253K |
| Treasury Stock | - |
| Retained Earnings | -$643M |
| Common Stock | $20K |
| Common Stock Shares Outstanding | $21K |
| Field | Value (None) |
|---|---|
| Operating Cashflow | -$4.4M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $22K |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | $922K |
| Profit Loss | - |
| Cashflow From Investment | - |
| Cashflow From Financing | $677K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$7.1M |
| Field | Value (None) |
|---|---|
| Gross Profit | $5.1M |
| Total Revenue | $8M |
| Cost Of Revenue | $2.9M |
| Costof Goods And Services Sold | $2.9M |
| Operating Income | -$7.7M |
| Selling General And Administrative | $6.9M |
| Research And Development | $1.8M |
| Operating Expenses | $13M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $22K |
| Income Before Tax | -$7.1M |
| Income Tax Expense | $39K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | - |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$6.7M |
| Ebitda | -$6.6M |
| Net Income | -$7.1M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Vyome Holdings, Inc. (Ticker: HIND) is an emerging clinical-stage biopharmaceutical company dedicated to the development of innovative therapeutic solutions targeting immuno-inflammatory and rare diseases. Located in Princeton, New Jersey, the company harnesses advanced research methodologies and state-of-the-art technologies to tackle significant unmet medical needs both in the United States and globally. With a robust pipeline of promising candidates, Vyome is strategically positioned to make a considerable impact in the healthcare sector, advancing the treatment of complex medical conditions.